Sophrosyne Pharmaceuticals has published preclinical data for SOPH110S in the peer reviewed journal, Cells. The article is entitled A Novel ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder: Preclinical Findings.

The findings supported FDA IND clearance and initiation of their Phase 1 study in Alcohol Use Disorder—an important step forward in the progress of transforming brain health therapeutics.

Raybow USA performed the initial racemic synthesis of SOPH-110.

The chiral separation was performed under Raybow’s GMP protocol (Lotus Separations LLC, Princeton, NJ, USA) and produced >98% chemical purity and >99% chiral purity. 

Read the article HERE. 

Connect with Raybow USA  for support with your integrated small-molecule CMC discovery, IND-enabling studies, and GMP manufacturing.

Use any of the “Contact Us” forms on this website or call the office at 828-884-8656 to start YOUR conversation about how Raybow USA services can support your next project on its journey from molecule to market. 

You can also message Nathaniel Kim, Sherida Johnson, Matthew Lauer, David Perrey, Tim Miley, Yuening Jiao, or Gary Richoux on LinkedIn to initiate a dialogue. 

#syntheticchemistry #analyticalchemistry #pharmaceuticals #specialtychemicals #cdmo #pharmaceuticalresearchanddevelopment #methoddevelopment #gmp #smallmolecule #Sophrosyne 

Molecule to Market, Raybow USA is your trusted partner!